Hyloris Successfully Raises Eur 15.0 Million In An Equity Offering By Means Of A Private Placement Via An Accelerated Bookbuild Offering

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) (the “Company” or “Hyloris”), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces today that it successfully raised an amount of EUR 15.0 million in gross proceeds, from new and existing, local and international investors, through an equity offering by means of a private placement via an accelerated bookbuild offering of 967,742 new shares (being approximately 3.7% of the Company's outstanding shares (pre-transaction)) at an issue price of EUR 15.50 per share (the "Offering"), representing a discount of 1.6% to the 30-day VWAP.